Jim Wilson move from UPENN to Biotech and what this means for Angelman syndrome.
“This is a great decision by Dr. Wilson and that of The University of Pennsylvania to get the development of these gene therapies out of academia and into a well-resourced biotech environment that can execute more efficiently. This is exciting news for rare disease and for other companies that can now leverage the expertise of […]